Axogen (AXGN) director Wendell McBride awarded 4,392 RSUs valued at $185,000

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.

Axogen, Inc. director Wendell Amy McBride received an annual equity grant of restricted stock units for service on the Board of Directors. The award covers 4,392 restricted stock units, each representing a right to receive one share of common stock, based on a $185,000 valuation as of the grant date. These units vest on June 24, 2027, the one-year anniversary of the grant date, and reflect compensation rather than an open‑market share purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wendell Amy McBride

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	4,392	$0.00	--

Holdings After Transaction: Restricted Stock Units — 4,392 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Key Figures

RSUs granted: 4,392 units Grant valuation: $185,000 Units per share right: 1 share per unit +3 more

6 metrics

RSUs granted 4,392 units Annual equity grant for Board service

Grant valuation $185,000 Valuation as of grant date for equity award

Units per share right 1 share per unit Each RSU represents one Axogen common share

Grant price per unit $0.00 per unit Compensation grant, not a cash purchase

Post-grant derivative holdings 4,392 RSUs Total derivative units following the transaction

Vesting date June 24, 2027 One-year anniversary of the grant date

Key Terms

Restricted Stock Units, Annual equity grant, vests

3 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Annual equity grant financial

"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."

vests financial

"The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 04:53 PM Accepted by SEC EDGAR 06/26/2026 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wendell Amy McBride

(Last)

(First)

(Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.

SUITE 400

(Street)

ALACHUA

FLORIDA

32615

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/24/2026		A		4,392		⁽²⁾	⁽²⁾	Common Stock	4,392	$0	4,392	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

2. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Remarks:

	/s/ Marc Began, as attorney-in-fact for Amy McBride-Wendell	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Axogen (AXGN) director Wendell Amy McBride report in this Form 4?

Wendell Amy McBride reported receiving 4,392 restricted stock units as an annual equity grant for service on Axogen’s Board of Directors. Each unit represents a right to one share of common stock, vesting after one year from the grant date.

How many Axogen (AXGN) restricted stock units were granted to Wendell Amy McBride?

The filing shows a grant of 4,392 restricted stock units to Wendell Amy McBride. These represent future rights to 4,392 shares of Axogen common stock, issued as part of annual Board compensation rather than a cash transaction or open‑market trade.

What is the value of the Axogen (AXGN) equity grant to Wendell Amy McBride?

The equity grant is based on a valuation of $185,000 as of the grant date. This valuation determines how many restricted stock units were awarded, resulting in 4,392 units granted as compensation for serving on Axogen’s Board of Directors.

When do Wendell Amy McBride’s Axogen (AXGN) restricted stock units vest?

The restricted stock units vest on June 24, 2027, which is the one-year anniversary of the grant date. Vesting means McBride will then receive the underlying Axogen common shares, assuming continued qualifying service on the Board until that date.

Is Wendell Amy McBride buying or selling Axogen (AXGN) shares in this Form 4?

This Form 4 reports an equity grant, not a market trade. McBride acquired 4,392 restricted stock units as compensation, at a stated price of $0.00 per unit, with shares to be delivered upon vesting rather than through open‑market buying or selling.